https://doi.org/10.4081/aiua.2023.11549

Calcification in Peyronie's disease: Its role and clinical influence on the various symptoms and signs of the disease, including psychological impact. Our study of 551 patients

Vol. 95 No. 3 (2023)
Submitted: June 27, 2023
Accepted: July 14, 2023
Published: September 12, 2023
Peyronie’s disease, Plaque calcification, Depression, Anxiety
Abstract Views: 668
PDF: 367
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Gianni Paulis
paulisg@libero.it
https://orcid.org/0000-0001-7312-1514
Peyronie’s Care Center, Department of Uro-Andrology, Castelfidardo Clinical Analysis Center, Rome, Italy.
Andrea Paulis
Neurosystem Center for applied Psychology and Neuroscience, Janet Clinical Centre, Rome, Italy.

Background: The aim of study was to evaluate the impact of plaque calcification on symptoms of patients with Peyronie’s disease (PD) and to evaluate mental health in PD patients with or without calcification. Methods: We performed a retrospective analysis of the clinical database of a single andrology clinic. We extracted 551 PD patients, and we sorted them into two groups: the first group included 201 PD patients with plaque calcification; the second group included 350 PD patients without plaque calcification. The inclusion criteria for both groups were as follows: aged between 21 and 81 years; thorough and available data on clinical history; baseline levels of blood glucose, glycosylated hemoglobin, cholesterol, and triglycerides; photographic documentation of the penile curvature; dynamic penile eco-color Doppler ultrasound with plaque measurements and volume calculation; and completion of the generalized anxiety disorder—7 questionnaire, patient health questionnaire—9 (for depression), visual analog scale for penile pain measurements, and the International Index of Erectile Function (IIEF) questionnaire. Results: Plaque calcification was present in 36.4% of cases. The presence of calcification affects the presence and severity of penile curvature. Calcification is associated with the presence of hypertension. In PD patients, the prevalence of significant anxiety and significant depression was 89.1% and 57.3%, respectively. Calcification is associated with the presence of anxiety and depression but does not lead to an increase in their prevalence. Conclusions: In PD patients, the calcification was present in more than one third of cases. The size of the plaque calcification was < 15 mm in most cases. Calcification influences the presence of the curve and influences its severity. There was a prominent prevalence of anxiety and depression in PD patients.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Bias WB, Nyberg Jr LM, Hochberg MC, et al. Peyronie's disease: a newly recognized autosomal-dominant trait. Am J Med Genet. 1982; 12:227-235.
Devine CJJ, Somers KD, Jordan GH, et al. Proposal: trauma as the cause of the Peyronie's lesion. J Urol. 1997; 157:285-290.
Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol. 1997; 158:1388-1390.
La Pera G, Pescatori ES, Calabrese M, et al. SIMONA Study Group. Peyronie's disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol. 2001; 40:525-530.
El-Sakka AI. Prevalence of Peyronie's disease among patients with erectile dysfunction. Eur Urol. 2006; 49:564-569.
Bjekic MD, Vlajinac HD, Sipetic SB, et al. Risk factors for Peyronie's disease: a case-control study. BJU Int. 2006; 97:570-574.
Carrieri MP, Serraino D, Palmiotto F, et al. A case-control study on risk factors for Peyronie's disease. J Clin Epidemiol. 1998; 51:511-515.
Ventimiglia E, Capogrosso P, Colicchia M, et al. Peyronie's disease and autoimmunity—a real-life clinical study and comprehensive review. J Sex Med. 2015; 12:1062-1069.
Tal R, Heck M, Teloken P, et al. Peyronie's disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010;7:1254-1261.
Paulis G, Paulis A, Perletti G. Congenital penile curvature as a possible risk factor for the onset of Peyronie's disease, and psychological consequences of penile curvature. Arch Ital Urol Androl. 2023; 95:11238.
Segundo A, Glina S. Prevalence, Risk Factors, and Erectile Dysfunction Associated With Peyronie's Disease Among Men Seeking Urological Care. Sex Med. 2020; 8:230-236.
Stuntz M, Perlaky A, des Vignes F, et al. The Prevalence of Peyronie's Disease in the United States: A Population-Based Study. PLoS One. 2016; 11:e0150157.
Bella AJ, Lee JC, Grober ED, et al. 2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature. Can Urol Assoc J. 2018; 12:E197-E209.
Johnson HM, Weerakoon P, Stricker PD. The incidence, aetiology, and presentation of Peyronie’s disease in Sydney, Australia. J Sex Disability. 2002; 20:109-116.
La Pera G, Pescatori ES, Calabrese M, et al. Peyronie's disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol. 2001; 40:525-530.
Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001; 88:727-30.
Rhoden EL, Teloken C, Ting HY, et al. Prevalence of Peyronie's disease in men over 50-y-old from Southern Brazil. Int J Impot Res. 2001; 13:291-293.
Shiraishi K, Shimabukuro T, Matsuyama H. The prevalence of Peyronie's disease in Japan: a study in men undergoing maintenance hemodialysis and routine health checks. J Sex Med. 2012; 9:2716-2723.
Wong A, Tsang SSl, O RYM, et al. MP33-12 Prevalence of Peyronie,e disease and its psychosexual impact in the Chinese population: a large cohort population-based cross-sectional study. J Urol. 2020; 203(Supplement 4):e499-e499.
Garaffa G, Trost LW, Serefoglu EC, et al. Understanding the course of Peyronie's disease. Int J Clin Pract. 2013; 67:781-788.
Levine LA, Larsen, S. Diagnosis and Management of Peyronie Disease. In: Campbell-Walsh Urology. 11th Ed., Wein AJ, Kavoussi LR, Partin AW, Peters CA, Eds.; Elsevier Saunders: Philadelphia (PA), 2015. Volume 1 (Chapter 31); 722–748.
Paulis G, De Giorgio G, Paulis L. Role of Oxidative Stress in Peyronie's Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants. Int J Mol Sci. 2022; 23:15969.
Vernet D, Nolazco G, Cantini L, et al. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol Reprod. 2005; 73:1199-1210.
Levine L, Rybak J, Corder C, et al. Peyronie's disease plaque calcification—Prevalence, time to identification, and development of a new grading classification. J Sex Med. 2013; 10:3121-3128.
Gelbard MK. Dystrophic penile calcification in Peyronie's disease. J Urol. 1988; 139:738-740.
Rainer QC, Rodriguez AA, Bajic P, et al. Implications of Calcification in Peyronie's Disease, A Review of the Literature. Urology. 2021; 152:52-59.
Andresen R, Wegner HEH, Miller K, et al. Imaging modalities in Peyronie's disease - an intrapersonal comparison of ultrasound sonography, X- ray in mammography technique, computerized tomography, and nuclear magnetic resonance in 20 patients. Eur Urol. 1998; 34:128-134.
Hauck EW, Hackstein N, Vosshenrich R, et al. Diagnostic value of magnetic resonance imaging in Peyronie's disease−a comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Urol. 2003; 43:293-299.
Pawlowska E, Bianek-Bodzak A. Imaging modalities and clinical assesment in men affected with Peyronie's disease. Pol J Radiol. 2011; 76:33-37.
McCauley JF, Dean C. Diagnostic utility of penile ultrasound in Peyronie’s disease. World J Urol. 2020; 38:263-268.
Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012; 62:543-552.
Parmar M, Masterson JM, Masterson 3rd TA. The role of imaging in the diagnosis and management of Peyronie's disease. Curr Opin Urol. 2020; 30:283-289.
Chou YH, Tiu CM, Pan HB, et al. High-resolution real-time ultrasound in Peyronie's disease. J Ultrasound Med. 1987; 6:67-70.
Kelâmi A. Autophotography in evaluation of functional penile disorders. Urology. 1983; 21:628-629.
Eri LM, Thomassen H, Brennhovd B, Håheim LL. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis. 2002; 5:273-278.
Lee JS, Chung BH. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens. Urol Int. 2007; 78:323-327.
Kahl C, Cleland JA. Visual analogue scale, numeric pain rating scale and the McGill pain Questionnaire: an overview of psychometric properties. Phys Ther Rev. 2005; 10:123-128.
Cepeda MS, Africano JM, Polo R, et al. What decline in pain intensity is meaningful to patients with acute pain? Pain. 2003; 105:151-157.
Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49:822-830.
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166:1092-1097.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16:606-613.
Bekos A, Arvaniti M, Hatzimouratidis K, et al. The natural history of Peyronie's disease: an ultrasonography-based study. Eur Urol. 2008; 53:644-650.
Pawłowska E, Bianek-Bodzak A. Imaging modalities and clinical assesment in men affected with Peyronie's disease. Pol J Radiol. 2011; 76:33-37.
Terrier JE, Nelson CJ. Psychological aspects of Peyronie's disease. Transl Androl Urol. 2016; 5:290-295.
Smith JF, Walsh TJ, Conti SL, et al. Risk factors for emotional and relationship problems in Peyronie’s disease. J Sex Med. 2008; 5:2179-2184.
Nelson CJ, Diblasio C, Kendirci M, et al. The chronology of depression and distress in men with Peyronie's disease. J Sex Med. 2008; 5:1985-1990.
Nelson CJ, Mulhall JP. Psychological impact of Peyronie's disease: a review. J Sex Med. 2013; 10:653-660.

How to Cite

Paulis, G., & Paulis, A. (2023). Calcification in Peyronie’s disease: Its role and clinical influence on the various symptoms and signs of the disease, including psychological impact. Our study of 551 patients. Archivio Italiano Di Urologia E Andrologia, 95(3). https://doi.org/10.4081/aiua.2023.11549
Copyright (c) 2023 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.